News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
80,755 Results
Type
Article (2602)
Company Profile (21)
Press Release (78132)
Section
Business (25398)
Career Advice (27)
Deals (5124)
Drug Delivery (2)
Drug Development (10303)
Employer Resources (3)
FDA (2007)
Job Trends (1057)
News (43450)
Policy (3899)
Tag
Academia (130)
Alliances (9105)
Alzheimer's disease (129)
Antibody-drug conjugate (ADC) (8)
Approvals (2014)
Artificial intelligence (10)
Bankruptcy (11)
Best Places to Work (788)
Biosimilars (12)
Biotechnology (20)
Breast cancer (11)
Cancer (161)
Cardiovascular disease (7)
Career advice (22)
CAR-T (10)
Cell therapy (36)
Clinical research (8502)
Collaboration (64)
Compensation (10)
COVID-19 (273)
C-suite (13)
Data (157)
Diabetes (12)
Diagnostics (611)
Drug discovery (12)
Earnings (8706)
Events (9091)
Executive appointments (45)
FDA (2093)
Funding (47)
Gene editing (10)
Gene therapy (24)
GLP-1 (51)
Government (271)
Healthcare (1441)
Infectious disease (278)
Inflammatory bowel disease (21)
Intellectual property (9)
IPO (1927)
Job creations (301)
Job search strategy (19)
Layoffs (14)
Legal (1001)
Liver cancer (16)
Lung cancer (25)
Lymphoma (16)
Manufacturing (28)
Medical device (1177)
Medtech (1178)
Mergers & acquisitions (3256)
Metabolic disorders (30)
Neuroscience (160)
NextGen Class of 2024 (357)
Non-profit (81)
Northern California (164)
Obesity (11)
Parkinson's disease (14)
Patents (17)
People (6374)
Phase I (2600)
Phase II (3647)
Phase III (3112)
Pipeline (61)
Postmarket research (262)
Preclinical (893)
Radiopharmaceuticals (23)
Rare diseases (23)
Real estate (704)
Regulatory (2801)
Research institute (152)
Series A (15)
Southern California (152)
Startups (518)
United States (1244)
Vaccines (30)
Date
Last 7 days (82)
Last 30 days (278)
Last 365 days (4156)
2024 (4123)
2023 (4932)
2022 (8446)
2021 (7879)
2020 (7035)
2019 (4570)
2018 (3513)
2017 (4184)
2016 (3695)
2015 (4579)
2014 (3399)
2013 (2892)
2012 (3024)
2011 (3157)
2010 (2945)
Location
Africa (91)
Asia (21850)
Australia (2459)
California (387)
Canada (181)
China (107)
Connecticut (16)
Europe (13350)
Florida (21)
Illinois (17)
Japan (41)
Maryland (101)
Massachusetts (227)
Minnesota (26)
New Jersey (144)
New York (103)
North Carolina (61)
Northern California (164)
Pennsylvania (60)
South America (113)
Southern California (152)
Texas (23)
Utah (8)
Virginia (10)
Washington State (13)
80,755 Results for "tilt biotherapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology Annual Meeting 2024.
May 28, 2024
·
4 min read
Press Releases
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
December 5, 2024
·
3 min read
Press Releases
TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
September 9, 2024
·
3 min read
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research Annual Meeting 2024.
April 10, 2024
·
4 min read
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
TILT Biotherapeutics announces it has been selected by the U.S. Department of Defense, America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.
February 14, 2024
·
4 min read
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
TILT Biotherapeutics presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference.
November 6, 2023
·
4 min read
Drug Development
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
TILT Biotherapeutics presented safety and efficacy data from its international Phase I trial in patients with metastatic melanoma, in an oral presentation at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
December 8, 2023
·
4 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Drug Development
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been dosed in a Phase I trial of the company’s oncolytic adenovirus TILT-123.
May 15, 2023
·
3 min read
Drug Development
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million round.
February 7, 2023
·
4 min read
1 of 8,076
Next
